Technology Summary

This innovation crafts MOF nanoparticles, self-assembling in water to encapsulate therapeutic agents like small molecules, DNA, RNA, or proteins. These nanoparticles feature an outer surface comprising an extracellular vesicle membrane (EVM), substantially extending their in vivo circulation half-life. By harnessing EVs from a patient’s autologous biological sample, including those from specific tissues and tumors, the invention achieves impressive loading efficiencies of up to 97% and a loading capacity of approximately 41%. In vitro and in vivo studies confirm the ability of these EV-like nanoparticles to shield proteins from protease degradation, evade immune clearance, selectively target tumor sites, facilitate uptake, and autonomously release the encapsulated protein post-internalization.